Phaseline

Targets › PDE4

PDE4: drug programs, companies and trials

4 programs from 4 companies in 10 trials: 7 Phase 3, 2 Phase 2, 1 Phase 1; Immunology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: the race on PDE4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupTQC3721 Suspension for Inhalation
Phosphodiesterase 3/4 (PDE3/4) inhibitor
PDE3, PDE4Phase 3Chronic Obstructive Pulmonary DiseaseFeb 2027
Boehringer IngelheimNerandomilast formulation 1
Phosphodiesterase 4 (PDE4) inhibitor
PDE4Phase 3Interstitial Lung Diseases; Idiopathic Pulmonary Fibrosis; Fibrosing Interstitial Lung Disease; Familial Pulmonary Fibrosis …Apr 2027
Scleroderma Research Foundation, Inc.BI 1015550 (Nerandomilast)
Phosphodiesterase-4 (PDE4) inhibitor
PDE4Phase 2Interstitial Lung Disease Due to Systemic DiseaseNov 2026
Palisade BioPALI-2108
phosphodiesterase-4 (PDE4) inhibitor
PDE4Phase 2Ulcerative Colitis (UC); Fibrostenotic Crohn's DiseaseOct 2027

Conditions

Interstitial Lung Diseases (2) Idiopathic Pulmonary Fibrosis (1) Fibrosing Interstitial Lung Disease (1) Familial Pulmonary Fibrosis (1) Systemic Sclerosis (1) Chronic Obstructive Pulmonary Disease (1) Ulcerative Colitis (UC) (1) Fibrostenotic Crohn's Disease (1) Interstitial Lung Disease Due to Systemic Disease (1)

Modalities

small molecule (3), mixed (1)

Companies

Boehringer Ingelheim (1) Chia Tai Tianqing Pharmaceutical Group (1) Palisade Bio (1) Scleroderma Research Foundation, Inc. (1)

Related targets

PDE3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.